Avacta cancer drug shows promise in patients as fresh cash raise launched

AIM-listed life sciences group Avacta Therapeutics has hailed a breakthrough in its hunt for new cancer treatments after its next-generation drug showed its controlled-release technology working in patients.

The company said early clinical data from AVA6103 demonstrated “proof of mechanism”, with the drug releasing the cancer-killing payload exatecan in patients for days after treatment.

The news came agroup launched a fresh capital raise to bolst... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...